S&P 500   3,791.76 (-1.50%)
DOW   30,609.57 (-1.06%)
QQQ   323.94 (-1.42%)
AAPL   142.62 (-0.38%)
MSFT   236.63 (+1.85%)
FB   274.64 (-2.63%)
GOOGL   1,835.00 (-3.82%)
AMZN   3,284.99 (-1.24%)
TSLA   888.05 (+0.56%)
NVDA   519.97 (-3.25%)
BABA   263.00 (-1.10%)
CGC   37.26 (+4.90%)
GE   10.88 (-3.63%)
MU   76.71 (-3.52%)
AMD   89.54 (-5.46%)
NIO   59.07 (-2.06%)
T   30.09 (+1.14%)
F   10.85 (-3.04%)
ACB   11.27 (+5.62%)
BA   196.73 (-2.64%)
DIS   163.27 (-3.71%)
NFLX   544.84 (-3.04%)
GILD   66.22 (-0.72%)
S&P 500   3,791.76 (-1.50%)
DOW   30,609.57 (-1.06%)
QQQ   323.94 (-1.42%)
AAPL   142.62 (-0.38%)
MSFT   236.63 (+1.85%)
FB   274.64 (-2.63%)
GOOGL   1,835.00 (-3.82%)
AMZN   3,284.99 (-1.24%)
TSLA   888.05 (+0.56%)
NVDA   519.97 (-3.25%)
BABA   263.00 (-1.10%)
CGC   37.26 (+4.90%)
GE   10.88 (-3.63%)
MU   76.71 (-3.52%)
AMD   89.54 (-5.46%)
NIO   59.07 (-2.06%)
T   30.09 (+1.14%)
F   10.85 (-3.04%)
ACB   11.27 (+5.62%)
BA   196.73 (-2.64%)
DIS   163.27 (-3.71%)
NFLX   544.84 (-3.04%)
GILD   66.22 (-0.72%)
S&P 500   3,791.76 (-1.50%)
DOW   30,609.57 (-1.06%)
QQQ   323.94 (-1.42%)
AAPL   142.62 (-0.38%)
MSFT   236.63 (+1.85%)
FB   274.64 (-2.63%)
GOOGL   1,835.00 (-3.82%)
AMZN   3,284.99 (-1.24%)
TSLA   888.05 (+0.56%)
NVDA   519.97 (-3.25%)
BABA   263.00 (-1.10%)
CGC   37.26 (+4.90%)
GE   10.88 (-3.63%)
MU   76.71 (-3.52%)
AMD   89.54 (-5.46%)
NIO   59.07 (-2.06%)
T   30.09 (+1.14%)
F   10.85 (-3.04%)
ACB   11.27 (+5.62%)
BA   196.73 (-2.64%)
DIS   163.27 (-3.71%)
NFLX   544.84 (-3.04%)
GILD   66.22 (-0.72%)
S&P 500   3,791.76 (-1.50%)
DOW   30,609.57 (-1.06%)
QQQ   323.94 (-1.42%)
AAPL   142.62 (-0.38%)
MSFT   236.63 (+1.85%)
FB   274.64 (-2.63%)
GOOGL   1,835.00 (-3.82%)
AMZN   3,284.99 (-1.24%)
TSLA   888.05 (+0.56%)
NVDA   519.97 (-3.25%)
BABA   263.00 (-1.10%)
CGC   37.26 (+4.90%)
GE   10.88 (-3.63%)
MU   76.71 (-3.52%)
AMD   89.54 (-5.46%)
NIO   59.07 (-2.06%)
T   30.09 (+1.14%)
F   10.85 (-3.04%)
ACB   11.27 (+5.62%)
BA   196.73 (-2.64%)
DIS   163.27 (-3.71%)
NFLX   544.84 (-3.04%)
GILD   66.22 (-0.72%)
Log in
NASDAQ:CGC

Canopy Growth Stock Forecast, Price & News

Followed 102 Times  
$37.26
+1.74 (+4.90 %)
(As of 01/27/2021 11:28 AM ET)
Add
Compare
Today's Range
$34.38
Now: $37.26▼
$37.32
50-Day Range
$24.26
MA: $28.36▼
$34.62
52-Week Range
$9.00
Now: $37.26▼
$36.15
Volume422,836 shs
Average Volume7.44 million shs
Market Capitalization$13.90 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis for recreational and medical purposes primarily in Canada, the United States, Germany, and the United Kingdom. It operates through two segments, Cannabis, Hemp and Other Consumer Products; and Canopy Rivers. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. As of February 14, 2020, it operated 28 cannabis retail stores under the Tweed or Tokyo Smoke name. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Canopy Growth logo

MarketRank™

Overall MarketRank™

0.71 out of 5 stars

Medical Sector

1188th out of 1,925 stocks

Medicinals & Botanicals Industry

13th out of 33 stocks

Analyst Opinion: 1.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGC
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.canopygrowth.com
Phone855 558 9333
Employees4,434
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.10
Current Ratio7.06
Quick Ratio5.84

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$297.34 million
Price / Sales46.75
Cash Flow$1.76 per share
Price / Cash Flow21.16
Book Value$10.97 per share
Price / Book3.40

Profitability

EPS (Most Recent Fiscal Year)$1.32
Net Income$-993,370,000.00
Net Margins-312.84%
Return on Equity-13.11%
Return on Assets-9.66%

Miscellaneous

Outstanding Shares373,076,000
Market Cap$13.90 billion
Next Earnings Date2/12/2021 (Estimated)
OptionableOptionable
$37.26
+1.74 (+4.90 %)
(As of 01/27/2021 11:28 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGC News and Ratings via Email

Sign-up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Canopy Growth (NASDAQ:CGC) Frequently Asked Questions

How has Canopy Growth's stock been impacted by COVID-19 (Coronavirus)?

Canopy Growth's stock was trading at $13.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CGC shares have increased by 175.0% and is now trading at $36.71.
View which stocks have been most impacted by COVID-19.

Is Canopy Growth a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Canopy Growth in the last year. There are currently 3 sell ratings, 9 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Canopy Growth stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CGC, but not buy additional shares or sell existing shares.
View analyst ratings for Canopy Growth or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Canopy Growth?

Wall Street analysts have given Canopy Growth a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Canopy Growth wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Canopy Growth's next earnings date?

Canopy Growth is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Canopy Growth.

How were Canopy Growth's earnings last quarter?

Canopy Growth Co. (NASDAQ:CGC) released its earnings results on Monday, November, 9th. The company reported $0.16 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.39. The business had revenue of $113.20 million for the quarter, compared to the consensus estimate of $87.71 million. Canopy Growth had a negative trailing twelve-month return on equity of 13.11% and a negative net margin of 312.84%.
View Canopy Growth's earnings history.

What price target have analysts set for CGC?

16 brokerages have issued twelve-month price objectives for Canopy Growth's shares. Their forecasts range from $21.10 to $40.00. On average, they expect Canopy Growth's share price to reach $31.51 in the next twelve months. This suggests that the stock has a possible downside of 14.2%.
View analysts' price targets for Canopy Growth or view Wall Street analyst' top-rated stocks.

Who are some of Canopy Growth's key competitors?

Some companies that are related to Canopy Growth include (ALIOF) (ALIOF), STADA Arzneimittel Aktiengesellschaft (STDAF), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), Aurora Cannabis (ACB), HEXO (HEXO), Sundial Growers (SNDL), Canopy Rivers (RIV), ChromaDex (CDXC), Charlie's (CHUC), MediWound (MDWD), Natural Alternatives International (NAII) and Glucose Health (GLUC).
View all of CGC's competitors.

Who are Canopy Growth's key executives?

Canopy Growth's management team includes the following people:
  • Mr. David Eric Klein, CEO & Director (Age 56, Pay $2.23M)
  • Mr. Rade Nikola Kovacevic, Pres & Chief Product Officer (Age 34, Pay $642.6k)
  • Mr. Michael Alan Lee, Exec. VP & CFO (Age 47, Pay $824.95k)
  • Mr. Thomas Carlton Stewart, VP & Chief Accounting Officer (Age 38, Pay $344.36k)
  • Mr. Phillip Stephen Shaer, Chief Legal Officer (Age 46, Pay $267.83k)
  • Mr. Timothy Rob Saunders, Strategic Advisor (Age 59, Pay $328.43k)
  • Mr. Andrew MacCorquodale, Interim COO & VP of Operations Transformation
  • Mr. Thomas Shipley IV, Sr. VP of Quality Assurance & Chief Science Officer (Age 31)
  • Ms. Holly Lukavsky, Chief HR Officer
  • Jason Green, Head of Agriculture - Hemp Division

What is Canopy Growth's stock symbol?

Canopy Growth trades on the NASDAQ under the ticker symbol "CGC."

Who are Canopy Growth's major shareholders?

Canopy Growth's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (0.05%), Kestra Advisory Services LLC (0.03%), V Wealth Advisors LLC (0.01%), Kestra Private Wealth Services LLC (0.01%), Boyd Watterson Asset Management LLC OH (0.01%) and NuWave Investment Management LLC (0.01%). Company insiders that own Canopy Growth stock include Phillip Stephen Shaer, Rade Nikola Kovacevic and Tomas Iv Shipley.
View institutional ownership trends for Canopy Growth.

Which major investors are selling Canopy Growth stock?

CGC stock was sold by a variety of institutional investors in the last quarter, including IFP Advisors Inc, and Investors Financial Group LLC. Company insiders that have sold Canopy Growth company stock in the last year include Phillip Stephen Shaer, Rade Nikola Kovacevic, and Tomas Iv Shipley.
View insider buying and selling activity for Canopy Growth or view top insider-selling stocks.

Which major investors are buying Canopy Growth stock?

CGC stock was bought by a variety of institutional investors in the last quarter, including V Wealth Advisors LLC, Kestra Advisory Services LLC, AdvisorShares Investments LLC, Lake Street Financial LLC, Boyd Watterson Asset Management LLC OH, NuWave Investment Management LLC, Tatro Capital LLC, and Calton & Associates Inc..
View insider buying and selling activity for Canopy Growth or or view top insider-buying stocks.

How do I buy shares of Canopy Growth?

Shares of CGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Canopy Growth's stock price today?

One share of CGC stock can currently be purchased for approximately $36.71.

How big of a company is Canopy Growth?

Canopy Growth has a market capitalization of $13.70 billion and generates $297.34 million in revenue each year. The company earns $-993,370,000.00 in net income (profit) each year or $1.32 on an earnings per share basis. Canopy Growth employs 4,434 workers across the globe.

What is Canopy Growth's official website?

The official website for Canopy Growth is www.canopygrowth.com.

How can I contact Canopy Growth?

Canopy Growth's mailing address is 1 HERSHEY DRIVE, SMITH FALLS A6, K7A0A8. The company can be reached via phone at 855 558 9333 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.